Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study

por Visentin, Andrea, Mauro, Francesca Romana, Catania, Gioachino, Fresa, Alberto, Vitale, Candida, Sanna, Alessandro, Mattiello, Veronica, Cibien, Francesca, Sportoletti, Paolo, Gentile, Massimo, Rigolin, Gian Matteo, Quaglia, Francesca Maria, Murru, Roberta, Gozzetti, Alessandro, Molica, Stefano, Marchetti, Monia, Pravato, Stefano, Angotzi, Francesco, Cellini, Alessandro, Scarfò, Lydia, Reda, Gianluigi, Coscia, Marta, Laurenti, Luca, Ghia, Paolo, Foà, Robin, Cuneo, Antonio, Trentin, Livio
Publicado 2022